![](data:image/png;base64,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)
REPERT MED CIR. 2022;31(2):155-160
160
de Medicina y Cirugía
3. Bello AK, Johnson DW, Feehally J, Harris D, Jindal K, Lunney M, et al.
Global Kidney Health Atlas (GKHA): design and methods. Kidney
Int. Suppl. 2017;7(2):145-53. doi: 10.1016/j.kisu.2017.08.001
4. Situación de la Enfermedad Renal Crónica, la Hipertensión Arterial
y la Diabetes Mellitus en Colombia 2017-2018 Bogotá: Fondo
Colombiano de Enfermedades de Alto Costo; 2018. p. 293.
5. Guillermo García Herrera H, Restrepo C, Alberto Buitrago Villa
C. Características clínicas e histológicas de las enfermedades
parenquimatosas renales en una muestra de biopsias renales
obtenidas entre el año 2002 y el 2017 en el departamento de
Caldas, Colombia. Rev. Colomb. Nefrol. 2018;5(2):107-117. doi:
10.22265/acnef.0.0.300
6. Yesid Coronado C, Echeverry I. Clinicopathological description of
glomerular diseases. Acta médica colombiana. 2016;41(2):125-9.
7. Glassock RJ. The Pathogenesis of Idiopathic Membranous
Nephropathy: A 50-Year Odyssey. Am J Kidney Dis. 2010;56(1):157-
67. doi: 10.1053/j.ajkd.2010.01.008
8. Pendergraft WF, Nachman PH, Jennette JC, Falk RJ. Enfermedad
glomerular primaria. In: Skorecki KMDFF, Chertow GMMD,
Marsden PAMD, Taal MWMMMDFCPF, Yu ASLMD, Wasser
WGMD, editors. Brenner y Rector El riñón2018. p. 1012-90.
9. Keri KC, Blumenthal S, Kulkarni V, Beck L, Chongkrairatanakul
T. Primary membranous nephropathy: comprehensive review and
historical perspective. Postgrad Med J Title. 2019;95(1119):23-31.
doi: 10.1136/postgradmedj-2018-135729
10. Beck LH, Jr., Bonegio Rg Fau - Lambeau G, Lambeau G Fau -
Beck DM, Beck Dm Fau - Powell DW, Powell Dw Fau - Cummins
TD, Cummins Td Fau - Klein JB, et al. M-type phospholipase
A2 receptor as target antigen in idiopathic membranous
nephropathy. N Engl J Med. 2009;361(1):11-21. doi: 10.1056/
NEJMoa0810457
11. Tomas NM, Beck LH, Jr., Meyer-Schwesinger C, Seitz-Polski B,
Ma H, Zahner G, et al. Thrombospondin type-1 domain-
containing 7A in idiopathic membranous nephropathy.
N Engl J Med. 2014;371(24):2277-2287. doi: 10.1056/
NEJMoa1409354
12. Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH,
Tang SCW, et al. Management and treatment of glomerular
diseases (part 1): conclusions from a Kidney Disease: Improving
Global Outcomes (KDIGO) Controversies Conference. Kidney
International. 2019;95(2):268-80. doi: 10.1016/j.kint.2018.10.018
13. Ponticelli C, Zucchelli P, Imbasciati E, Cagnoli L, Pozzi C, Passerini
P, et al. Controlled Trial of Methylprednisolone and Chlorambucil
in Idiopathic Membranous Nephropathy. N Engl J Med.
1984;310(15):946-50. doi: 10.1056/NEJM198404123101503
14. Aldana I, Diazgranados I, Gustavo AM, García R. Respuestas al
esquema ponticelli en pacientes con nefropat+ia membranosa
idiopatica. Barranquilla 2011-2013. Barranquilla 2011- 2013.
Biociencias. 2014;9(1):23-9.
15. Mathrani V, Alejmi A, Grin S, Roberts G. Intravenous
cyclophosphamide and oral prednisolone is a safe and eective
treatment option for idiopathic membranous nephropathy. Clin
Kidney J. 2017;10(4):450-454. doi: 10.1093/ckj/sfw152
16. Gustavo AM, Gaviria Garcia G, Sierra Llamas C, Elena
Lastre-Amell G. Valorar el seguimiento y cumplimiento
integral de adherencia al tratamiento en pacientes con nefritis
lúpica. Investig Enferm Imagen Desarr. 2018;20(1). doi: 10.11144/
Javeriana.ie20-1.vsci
17. Thompson A, Cattran DC, Blank M, Nachman PH. Complete
and Partial Remission as Surrogate End Points in Membranous
Nephropathy. J Am Soc Nephrol. 2015;26(12):2930-7. doi:
10.1681/ASN.2015010091
18. Ponticelli C, Altieri P Fau - Scolari F, Scolari F Fau - Passerini
P, Passerini P Fau - Roccatello D, Roccatello D Fau - Cesana B,
Cesana B Fau - Melis P, et al. A randomized study comparing
methylprednisolone plus chlorambucil versus methylprednisolone
plus cyclophosphamide in idiopathic membranous nephropathy. J
Am Soc Nephrol. 1998;9(3):444-50. doi: 10.1681/ASN.V93444
19. de Groot K, Harper L Fau - Jayne DRW, Jayne Dr Fau - Flores
Suarez LF, Flores Suarez Lf Fau - Gregorini G, Gregorini G Fau -
Gross WL, Gross Wl Fau - Luqmani R, et al. Pulse versus daily oral
cyclophosphamide for induction of remission in antineutrophil
cytoplasmic antibody-associated vasculitis: a randomized trial.
(1539- Ann Intern Med. 2009;150(10):670-80. doi: 10.7326/0003-
4819-150-10-200905190-00004
20. Kanigicherla DAK, Hamilton P, Czapla K, Brenchley PE. Intravenous
pulse cyclophosphamide and steroids induce immunological
and clinical remission in New-incident and relapsing primary
membranous nephropathy. Nephrology (Carlton). 2018;23(1):60-
68. doi: 10.1111/nep.12955
21. Faurschou M, Sorensen Ij Fau - Mellemkjaer L, Mellemkjaer L Fau
– Loft AGR, Loft Ag Fau - Thomsen BS, Thomsen Bs Fau - Tvede
N, Tvede N Fau - Baslund B, et al. Malignancies in Wegener's
granulomatosis: incidence and relation to cyclophosphamide
therapy in a cohort of 293 patients. J Rheumatol. 2008;35(1):100-5
22. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen
FE, Lynch CF, et al. Bladder and kidney cancer following
cyclophosphamide therapy for non- Hodgkin’s lymphoma. J Natl
Cancer Inst. 1995;87(7):524-30. doi: 10.1093/jnci/87.7.524
23. Muller-Deile J, Schier L, Hiss M, Haller H, Schier M. A
new rescue regimen with plasma exchange and rituximab in
high-risk membranous glomerulonephritis. Eur J Clin Invest.
2015;45(12):1260-9. doi: 10.1111/eci.12545
24. Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA,
Aslam N, et al. Rituximab or Cyclosporine in the Treatment of
Membranous Nephropathy. N Engl J Med. 2019;381(1):36-46. doi:
10.1056/NEJMoa1814427
25. Ruggenenti P, Remuzzi G. A First Step toward a New Approach
to Treating Membranous Nephropathy. N Engl J Med.
2019;381(1):86-88. doi: 10.1056/NEJMe1906666